RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 201 shares, a drop of 40.5% from the June 30th total of 338 shares. Based on an average daily volume of 338 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.0% of the company’s shares are sold short.
RCN Pareto Strategic Allocation ETF Stock Performance
Shares of NYSEARCA:PRTO traded up $0.43 during trading on Thursday, reaching $27.19. The stock had a trading volume of 106 shares. RCN Pareto Strategic Allocation ETF has a 52 week low of $24.68 and a 52 week high of $28.16. The firm has a market cap of $603.05 million, a P/E ratio of -28.32 and a beta of 0.60.
One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.
Featured Stories
- Five stocks we like better than RCN Pareto Strategic Allocation ETF
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for RCN Pareto Strategic Allocation ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RCN Pareto Strategic Allocation ETF and related companies with MarketBeat.com's FREE daily email newsletter.
